News

Explore

NovalGen announces data presentation at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia

Sep 17, 2021

NovalGen doses first patient in Phase I study in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma

Jun 09, 2021

NovalGen presents data at American Society of Clinical Oncology for novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma

May 20, 2021

NovalGen receives CTA approval to start a Phase 1/2 first in human study to evaluate the safety, pharmacokinetics and efficacy of NVG-111 in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma

Apr 07, 2021

NovalGen enters strategic partnership with HALIX B.V. to manufacture clinical trial materials

Feb 22, 2021

NovalGen announces updates to its executive management team

Feb 19, 2021

Publications

Publications